Divi’s is the pharma kid in class who doesn’t sell tablets to patients but sells the raw drugs to companies that do. With APIs, intermediates, and nutraceutical carotenoids, it quietly supplies to 12 of the top 20 global pharma giants. Market cap ₹1.6 lakh crore, almost debt-free, 32% operating margins, and P/E of 69 – yes, investors are paying Gucci prices for a factory that mostly makes chemical powders.
2. Introduction
Incorporated in 1990, Divi’s is like the Amazon Basics of the pharma world – they don’t care about your brand name, they just manufacture the ingredients that go inside. From antidepressants and antivirals to nutraceuticals like Beta-Carotene, Divi’s churns out APIs in tonnage that would make a cement company jealous.
Exports? 90%. Their customers? Big Pharma royalty across the US, EU, Japan. India gets barely 10% of their attention – probably because here everyone argues for discounts on paracetamol strips.
Financially, Divi’s is a curious beast. Sales growth is crawling (12% CAGR over 5 years), profits have been volatile, but margins remain 30%+. How? By focusing on niche APIs and custom synthesis contracts that keep foreign clients locked in for a decade. It’s like they signed a long-term Netflix plan with no cancel option.
But at P/E 69, the stock trades as if they’re inventing a cure for heartbreak.
Would you pay luxury hotel rates for a company whose product list includes good old Naproxen (painkiller)?
3. Business Model – WTF Do They Even Do?
Divi’s has three business legs, like a pharma tripod:
Generic APIs (Big Daddy Revenue): 30 high-volume APIs like Naproxen, Gabapentin, Pregabalin, Quetiapine. These are blockbuster generics exported in bulk.
Custom Synthesis: Manufacturing APIs and intermediates for global innovators. 12 of the top 20 pharma companies are long-term clients. Translation: “Big Pharma trusts us not to mess up their billion-dollar drug recipes.”
Nutraceuticals: Carotenoids (Beta-Carotene, Lycopene, Astaxanthin, etc.). Basically, the stuff added in health drinks, supplements, and overpriced energy powders.
Revenue split? 98% product sales, 2% “other.” Meaning – they don’t earn from “jugaad,” just pure manufacturing.
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
2,410
2,118
2,585
+13.8%
-6.8%
EBITDA
729
622
886
+17.2%
-17.7%
PAT
545
430
662
+26.7%
-17.7%
EPS (₹)
20.5
16.2
24.9
+26.5%
-17.7%
Commentary: YoY growth strong, QoQ decline evident. EPS annualized = ₹82. Stock P/E = 69. Investors are basically saying: “We’ll pay today for the Divi’s of 2035.”
